Insulin Secretion and Insulin Resistance in Newly Diagnosed, Drug Naive Prediabetes and Type 2 Diabetes Patients With / Without Metabolic Syndrome
Sang Youl Rhee, Suk Chon, Seungjoon Oh, Sung Woon Kim, Jin-Woo Kim, Young Seol Kim, and Jeong-taek Woo, Department of Endocrinology and Metabolism, Research Institute of Endocrinology, College of Medicine, Kyung Hee University, Seoul, Korea
Introduction
The pathogenesis of diabetes is complicated
by several metabolism-related problems. In particular, a
deterioration in insulin secretion and an aggravation of
insulin resistance are known to be essentials in the primary
pathogenesis of type 2 diabetes mellitus (DM) [1]. In terms
of insulin resistance, type 2 DM and metabolic syndrome (MS)
are closely related. The Botnia study showed that 84% of
men and 78% of women with type 2 DM had accompanying MS.
For patients with prediabetes, 64% of men and 42% of women
had MS, and for normal glucose tolerance (NGT) groups, only
15% of men and 10% of women had MS [2]. However, not all
type 2 DM patients have MS and neither do all MS patients
have accompanying type 2 DM. This signifies that even though
these two diseases have much in common, they differ pathophysiologically.
For these reasons, we undertook this study to compare differences
in type 2 DM according to the co-existence of MS with respect
to insulin secretion and insulin resistance. To exclude the
effect of artificial intervention or severe βbeta-cell
dysfunction, the subjects enrolled in this study were confined
to newly diagnosed and drug naive.
Subjects and Methods
SUBJECTS
This study was carried out on 322 subjects suspected of
having type 2 DM. In order to avoid severe βbeta-cell
dysfunction and to exclude any change in insulin secretory
function or insulin resistance due to artificial intervention,
study subjects were confined to having a history of hyperglycemia
of less than three months and no history of taking a medication
that might affect glucose metabolism.
METHODS
To diagnose type 2 DM, we used oral glucose tolerance test (OGTT). Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, and HbA1c were measured before carrying out OGTT.
According to OGTT results, subject were divided into three groups: a normal glucose tolerance (NGT) group, a prediabetes (preDM) group, comprised of an impaired fasting glucose (IFG) group and/or an impaired glucose tolerance (IGT) group, and a type 2 diabetes mellitus (T2DM) group. And, HOMA-IR (the insulin resistance index) and IGI (insulinogenic index, which means the insulin secretion ability index) were calculated for all subjects who underwent OGTT [3].
HOMA-IR = (Ins0 x Glc0)/22.5
IGI = (Ins30 - Ins0) / 18 (Glc30 - Glc0)
Ins0: fasting plasma insulin (mIU/L)
Ins30: insulin 30 minutes after glucose intake (mIU/L)
Glc0: fasting plasma glucose (mmol/L)
Glc30: plasma glucose 30 minutes after glucose intake (mmol/L)
Study subjects were stratified according to the presence of MS and were diagnosed according to adult treatment panel (ATP) III diagnostic criteria of MS of the National Cholesterol Education Program (NCEP) by using basic anthropometric data, OGTT results, and lipid profiles [4]. However, for MS diagnosis, abdominal circumference thresholds were taken as 90 cm for men and 80 cm for women, according to the Asian-Pacific abdominal obesity guidelines [5]. By using the indices mentioned above, the three subject groups were subdivided into 6 subgroups; i.e. NGT, preDM, and T2DM, each with/without MS. The clinical characteristics, insulin secretory functions, and insulin resistances of these subgroups were compared.
Results
CLINICAL CHARACTERISTICS OF THE STUDY SUBJECTS
According to OGTT results, 63 subjects were diagnosed with normal glucose tolerance, 81 subjects with impaired fasting blood glucose and/or impaired glucose tolerance and 178 with type 2 DM. According to ATP III criteria modified in-line with the Asian-Pacific guidelines, 218 subjects (67.7% of total) were diagnosed with MS. When subjects in the three main groups were compared, 34.9% of the NGT group had MS, whereas 60.5% of the prediabetes group, and 82.6% of the type 2 DM group had MS (Figure 1).
Figure 1. Prevalence of Metabolic syndrome among study subjects
COMPARISONS OF HOMA-IR AND IGI ACCORDING TO GLUCOSE TOLERANCE AND METABOLIC SYNDROME
On comparing the 3 groups stratified by the presence of MS, mean HOMA-IR and IGI were higher in those with MS. However, in the case of the prediabetes and type 2 DM groups those with MS, showed significantly higher HOMA-IR and IGI values than those without, whereas in the NGT subgroup, HOMA-IR and IGI levels were not dependent on the presence of MS.
When the three groups were subdivided according to the presence of MS and examined with respect to glucose tolerance, the NGT, preDM, and type 2 DM subgroups in MS group showed significant higher HOMA-IR and lower IGI according to glucose tolerance. On the other hand, the NGT, preDM, and type 2 DM subgroups in non-MS group showed a significant decrease in IGI but no significant difference in HOMA-IR as glucose tolerance worsened.
Conclusion
These findings suggest that deterioration in IGI and aggravation of HOMA-IR are both important in the primary pathogenesis of diabetes in those with MS. However, IGI deterioration may be the only important factor in the primary pathogenesis of T2DM in the absence of MS. Even though their proportions are relatively small, there exist type 2 DM patients whose disease cannot be explained by the current pathogenic theory - compensatory insulin deterioration against a background of insulin resistance aggravation (Figure 2).
Prospective studies that overcome the present study’s limitations, comparative studies between races, and work at the molecular level would empower us to present a clearer view of the comparative characteristics, relationships, and pathophysiologies of MS and early stage type 2 DM.
Figure 2. Hypothesis concerning primary metabolic changes during the development of type 2 DM. In patients with MS, IGI (compensatory insulin secretion) deterioration and HOMA-IR (insulin resistance) aggravation are both important in the primary pathogenesis of diabetes. However, HOMA-IR aggravation may not be an important factor in the pathogenesis of diabetes in those without MS.
Acknowledgement
This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health &Welfare, Republic of Korea (Grant No. A050463).
References
- DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88(IX):787-835.
- Tripathy D, Carlsson N, Almgren P. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000;49:975-80.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
- The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available from http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf
Please address correspondence to:
Jeong-taek Woo, M.D., Ph.D.
Department of Endocrinology and Metabolism
College of Medicine
Kyung Hee University
Seoul, Korea.
Tel: 82-2-958-8128
Fax: 82-2-968-1848
E-mail: jtwoomd@khmc.or.kr
|
